Labiotech.eu

antibody drug conjugate adc small cancer treatment

News and Trends 30 Nov 2022

SOTIO exercises option on ADC program

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, has exercised its first of five exclusive, target-specific options with LegoChem Biosciences (LCB) for antibody-drug conjugate (ADC) SOT106, which is currently being evaluated in preclinical studies of solid tumor indications. In November 2021, SOTIO and LCB entered into a multi-target exclusive collaboration and license […]

November 30, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 30 Nov 2022

AstraZeneca splashes out up to $320M on T-cell receptor therapy company

Neogene Therapeutics, Inc., a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts), has entered into a definitive agreement to be acquired by Astrazeneca. AstraZeneca will acquire all outstanding equity of Neogene Therapeutics for a total consideration of up to $320 million, on a cash and debt free […]

November 30, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Nov 2022

Touchlight receives new grant to further develop doggybone DNA vaccine platform

UK-based biotechnology company, Touchlight, has received a new grant from the Bill & Melinda Gates Foundation. The company will use the money to further its pre-clinical development of its doggybone DNA vaccine platform. The program aims to build on evidence that Touchlight’s rapid enzymatic doggybone DNA vaccines can produce strong neutralizing antibodies and durable T […]

November 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 29 Nov 2022

Biocomposites antibiotic carrier, STIMULAN, receives approval for use in Mexico

UK-based medical devices company, Biocomposites Ltd., has announced that antibiotic carrier STIMULAN has received a new broad-based approval for use in bone and soft tissue in Mexico. The approval, granted by COFEPRIS, the Mexican Regulatory Authority, authorizes the use of STIMULAN as a carrier of substances such as antibiotics that are chosen by the surgeon […]

November 29, 2022 - 2 minutesmins - By Liza Laws

immutep checkpoint inhibitor lag 3 cancer

Interview 29 Nov 2022

LAG-3: The next big checkpoint inhibitor target

Since their first approval a decade ago, immune checkpoint inhibitors have been gaining momentum in the treatment of cancer. The Australian-French firm Immutep explains why the immune checkpoint target LAG-3 is ripe for innovation in the space. Immune checkpoint inhibitors have revolutionized the field of immuno-oncology in the last decade, especially since the approval of […]

November 29, 2022 - 7 minutesmins - By Jonathan Smith

News and Trends 29 Nov 2022

Mycotechnology and IFF join forces in Europe to create better food system

Mycotechnology, a company using mycelia, the roots of mushrooms, and IFF have formed a partnership to co-develop alternative proteins. The two companies have already partnered in the U.S. and the new collaboration in Europe, they say, reflects their shared commitment of bringing a better food system and ‘next-generation’ food and drink products to the European […]

November 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 29 Nov 2022

BioPharma Dynamics expands to provide more solutions for cell and gene therapy industry

BioPharma Dynamics have expanded their portfolio for the cell and gene therapy market to offer a range of chemically defined T-Cell media, DMSO-free cryopreservation solutions, and recombinant growth factors. Suitable for cell therapy applications at any stage, the portfolio of cell media products include immune cell media, stem cell media, and cell cryopreservation solutions. Supporting applications which […]

November 29, 2022 - 2 minutesmins - By Liza Laws

News and Trends 28 Nov 2022

Molecure to conduct cancer treatment trial in Poland

Molecure S.A. says the President of the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products has given the company permission to conduct the first clinical trial of OATD-02. The planned phase I trial will be an open-label, multi-center, dose escalation study to evaluate safety, tolerability, anti-cancer activity and to establish the […]

November 28, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Deep Science Ventures and AbbVie to create companies to target inflammatory diseases

Deep Science Ventures (DSV), a London-based venture creator, is teaming up with AbbVie, a global pharmaceutical company, to build one or more new companies targeting immune-mediated inflammatory diseases. Together, the partners said they aim to unlock new approaches that not only make disease treatment better, but also present potential cures for patients. Immune-mediated inflammatory diseases […]

November 28, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Replay receives $1.5M grant for hypoimmunogenic technology platform

Genome writing company Replay has received a $1.56 million grant from the Bill & Melinda Gates Foundation to accelerate the development of uCell, a proprietary hypoimmunogenic technology platform. Replay’s uCell platform is an off-the-shelf, genomically rewritten, hypoimmunogenic technology that allows allogeneic donor-derived primary cells and iPSCs (induced pluripotent stem cells) to be made immune silent. […]

November 28, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Localizing BRCA gene mutations to better treat ovarian cancer

Mutations of BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 people respectively, significantly increase the risk of certain cancers such as ovarian, breast, pancreatic and prostate cancer. In 2016, a new class of drugs, PARP inhibitors, was found to be highly effective against BRCA mutation-related tumors. However, almost […]

November 28, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 28 Nov 2022

Biomemory raises €5M to advance DNA digital data storage solution

Biomemory, a start-up focused on DNA data synthesis and storage, has closed a €5 million ($5.2 million) seed investment for the development of its technology. The seed funding round was led by eureKARE and the French Tech Seed Fund, managed on behalf of the French State by Bpifrance within the scope of France 2030, with […]

November 28, 2022 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

SOTIO exercises option on ADC program

AstraZeneca splashes out up to $320M on T-cell receptor therapy company

Touchlight receives new grant to further develop doggybone DNA vaccine platform

Biocomposites antibiotic carrier, STIMULAN, receives approval for use in Mexico

LAG-3: The next big checkpoint inhibitor target

Mycotechnology and IFF join forces in Europe to create better food system

BioPharma Dynamics expands to provide more solutions for cell and gene therapy industry

Molecure to conduct cancer treatment trial in Poland

Deep Science Ventures and AbbVie to create companies to target inflammatory diseases

Replay receives $1.5M grant for hypoimmunogenic technology platform

Localizing BRCA gene mutations to better treat ovarian cancer

Biomemory raises €5M to advance DNA digital data storage solution

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!